ArticleJournal of translational medicine2026
Human single-cell atlas of proliferative diabetic retinopathy reveals a SOX15-overexpressing stromal population driving retinal fibrosis through the endothelin-1 -EDNRB axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProliferative diabetic retinopathy (PDR) is a leading cause of irreversible blindness worldwide, characterized by pathological neovascularization and progressive retinal fibrosis. Although anti-VEGF therapy effectively suppresses neovascularization, it does not address fibrovascular membranes (FVMs) formation and may paradoxically accelerate membrane contraction, increasing the risk of tractional retinal detachment. The lack of effective anti-fibrotic strategies highlights the importance to elucidate the key cellular mechanisms underlying retinal fibrosis in PDR.
methodsWe performed single-cell RNA sequencing (scRNA-seq) on primary retinal tissues from PDR organ donors and non-diabetic controls, generating a single-cell transcriptomic atlas of the human PDR retina. Critical findings were validated by immunofluorescence, in vivo and in vitro functional assays. Stromal-specific Sox15 conditional knockout mice in a two-stage laser-induced fibrosis model and siRNA-mediated knockdown in fibroblasts, and intravitreal administration of the EDNRB antagonist were performed.
resultsscRNA-seq of primary human PDR retinas generated the first comprehensive single-cell transcriptomic atlas of human PDR, revealing profound alterations in cellular composition including microglial expansion and Müller glia reprogramming as central neuroinflammatory features of PDR, and selective loss of metallothionein enriched rods subpopulation and S-cones. Notably, We identified a stromal cell population that was enriched in PDR retinas, localized in FVMs, and characterized by high SOX15 expression. Cell-cell communication analysis revealed that EDN1-EDNRB signaling between these stromal cells and Müller glia represented the most prominent intercellular interaction in PDR. Mechanistically, SOX15 regulates EDN1 transcription through binding to its promoter, driving EDN1 expression that activates EDNRB-expressing retinal macroglia to promote reactive gliosis and retinal fibrosis. Stromal-specific Sox15 conditional knockout significantly attenuated fibrotic lesion formation in vivo, and PDR-derived fibrocytes with elevated SOX15 exhibited enhanced fibroblast differentiation and EDN1 secretion, providing translational validation in human disease. Intravitreal EDNRB blockade with BQ-788 significantly reduced fibrotic area in a murine fibrosis model.
conclusionsThis study identifies key pathological features of the human PDR retina, including pervasive neuroinflammation and selective loss of photoreceptor subpopulations, and delineates the SOX15-EDN1-EDNRB axis as a novel mechanism driving retinal fibrosis. Targeting this axis may represent a promising anti-fibrotic strategy for advanced PDR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.